

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

DICTIONARY FILE UPDATES: 31 JAN 2008 HIGHEST RN 1001228-41-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10706328.str



chain nodes :

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46  
47 48 49 50

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25

chain bonds :

1-36 2-35 3-34 4-27 7-28 8-11 9-29 10-32 15-33 16-37 17-38 18-20 19-39  
21-40 21-41 22-42 22-43 23-26 24-46 24-47 25-44 25-45 26-48 26-49 26-50  
28-30 28-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-15 12-13 13-14  
13-16 14-15 14-19 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25

exact/norm bonds :

5-7 6-10 7-8 7-28 8-9 9-10 9-29 11-12 11-15 12-13 14-15 18-20 20-21  
20-25 21-22 22-23 23-24 23-26 24-25

exact bonds :

1-36 2-35 3-34 4-27 8-11 10-32 15-33 16-37 17-38 19-39 21-40 21-41  
22-42 22-43 24-46 24-47 25-44 25-45 26-48 26-49 26-50 28-30 28-31

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-16 14-19 16-17 17-18 18-19

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS  
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS  
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS  
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa  
SAMPLE SEARCH INITIATED 15:01:56 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7 TO 298  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA EXA SAM L1


=> s l1 exa full  
FULL SEARCH INITIATED 15:02:01 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 226 TO ITERATE

100.0% PROCESSED 226 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

L3 2 SEA EXA FUL L1

=> d l3


L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 692737-81-8 REGISTRY  
ED Entered STN: 14 Jun 2004  
CN 2(1H)-Quinolinone-4-14C, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)  
MF C21 H21 F N6 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d l3 1-2

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 692737-81-8 REGISTRY  
ED Entered STN: 14 Jun 2004  
CN 2(1H)-Quinolinone-4-14C, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)  
MF C21 H21 F N6 O  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 405169-16-6 REGISTRY  
ED Entered STN: 12 Apr 2002  
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 2(1H)-Quinolinone, 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]- (9CI)  
OTHER NAMES:  
CN 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one  
CN Dovitinib  
DR 804551-71-1  
MF C21 H21 F N6 O  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
66.77	66.98

FILE 'MEDLINE' ENTERED AT 15:02:32 ON 01 FEB 2008

FILE 'CAPLUS' ENTERED AT 15:02:32 ON 01 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:02:32 ON 01 FEB 2008  
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:02:32 ON 01 FEB 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12

SAMPLE SEARCH INITIATED 15:02:36 FILE 'WPIDS'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 0 TO 0  
PROJECTED ANSWERS: 0 TO 0

L4 0 L2

=> s 13

SAMPLE SEARCH INITIATED 15:02:44 FILE 'WPIDS'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 0 TO 0  
PROJECTED ANSWERS: 0 TO 0

L5 41 L3

=> s 15 and (cmax or auc)

L6 2 L5 AND (CMAX OR AUC)

=> d 16 1-2 ibib, abs

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2005:299638 USPATFULL

TITLE: Inhibition of FGFR3 and treatment of multiple myeloma

INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES

Chou, Joyce, El Cerrito, CA, UNITED STATES

Harwood, Eric, Seattle, WA, UNITED STATES

Heise, Carla C., Benicia, CA, UNITED STATES

Machajewski, Timothy D., Martinez, CA, UNITED STATES

Ryckman, David, Bellevue, WA, UNITED STATES

Shang, Xiao, Bellevue, WA, UNITED STATES

Wiesmann, Marion, Brisbane, CA, UNITED STATES

Zhu, Shuguang, Shoreline, WA, UNITED STATES

PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005261307	A1	20051124
APPLICATION INFO.:	US 2004-983174	A1	20041105 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)
	US 2003-526426P	20031202 (60)

US 2003-526425P	20031202 (60)
US 2004-546017P	20040219 (60)
US 2002-405729P	20020823 (60)
US 2002-426107P	20021113 (60)
US 2002-426226P	20021113 (60)
US 2002-426282P	20021113 (60)
US 2002-428210P	20021121 (60)
US 2003-460328P	20030403 (60)
US 2003-460493P	20030403 (60)
US 2003-460327P	20030403 (60)
US 2003-478916P	20030616 (60)
US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 34 Drawing Page(s)  
LINE COUNT: 17221  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:280895 USPATFULL  
TITLE: Methods of treating cancer and related methods  
INVENTOR(S): Hannah, Alison, Sebastopol, CA, UNITED STATES  
Harwood, Eric, Seattle, WA, UNITED STATES  
Haroldsen, Peter, Pacifica, CA, UNITED STATES  
Heise, Carla, Benecia, CA, UNITED STATES  
Machajewski, Timothy, Martinez, CA, UNITED STATES  
Samara, Emil, Danville, CA, UNITED STATES  
Shang, Xiao, Bellevue, WA, UNITED STATES  
Vora, Jayesh, Martinez, CA, UNITED STATES  
Zhu, Shuguang, Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220196	A1	20041104
APPLICATION INFO.:	US 2003-706328	A1	20031112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-460369P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460328P	20030403 (60)
	US 2002-426204P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-426107P	20021113 (60)
	US 2003-517915P	20031107 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.

Box 8097, Emeryville, CA, 94662-8097

NUMBER OF CLAIMS: 58  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 2045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008

L1 STRUCTURE UPLOADED  
L2 0 S L1 EXA  
L3 2 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:02:32 ON 01 FEB 2008

L4 0 S L2  
L5 41 S L3  
L6 2 S L5 AND (CMAX OR AUC)

=> s l5 and (cancer or tumor)  
L7 27 L5 AND (CANCER OR TUMOR)

=> s l7 and "tyrosine kinase"  
L8 23 L7 AND "TYROSINE KINASE"

=> d l8 1-23 ibib, abs

L8 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1225966 CAPLUS

DOCUMENT NUMBER: 146:722

TITLE: Methods for treating drug resistant cancer

INVENTOR(S): Michelson, Glenn C.; Chan, Vivien W.; Heise, Carla C.;  
Wiesmann, Marion; Dawes, Timothy D.

PATENT ASSIGNEE(S): Novartis AG, USA

SOURCE: PCT Int. Appl., 151pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006124413	A2	20061123	WO 2006-US17922	20060510
WO 2006124413	A3	20070607		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,



SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006247803 A1 20061123 AU 2006-247803 20060510  
 PRIORITY APPLN. INFO.: US 2005-680722P P 20050513  
 WO 2006-US17922 W 20060510

OTHER SOURCE(S): MARPAT 146:722

AB This invention pertains generally to methods of treating cancer.  
 More specifically, the invention pertains to methods and 4-amino  
 substituted quinolinone benzimidazolyl compds. such as  
 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-  
 yl]quinolin-2(1H)-one compds. and pharmaceutical formulations comprising  
 such compds. for treating drug-resistant cancer and patients  
 with drug resistant cancer.

L8 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:763835 CAPLUS  
 DOCUMENT NUMBER: 145:202872  
 TITLE: Treatment of metastasized tumors  
 INVENTOR(S): Lopes De Menezes, Daniel; Heise, Carla; Xin, Xiaohua  
 PATENT ASSIGNEE(S): Chiron Corporation, USA  
 SOURCE: PCT Int. Appl., 101pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006081445	A2	20060803	WO 2006-US2979	20060127
WO 2006081445	A3	20070111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006208012	A1	20060803	AU 2006-208012	20060127
CA 2596084	A1	20060803	CA 2006-2596084	20060127
US 2006183750	A1	20060817	US 2006-342257	20060127
EP 1845990	A2	20071024	EP 2006-733986	20060127
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2007118596	A	20071217	KR 2007-719428	20070824
NO 2007004360	A	20071025	NO 2007-4360	20070827
PRIORITY APPLN. INFO.:			US 2005-647568P	P 20050127
			US 2005-669245P	P 20050406
			US 2005-722053P	P 20050929
			WO 2006-US2979	W 20060127

OTHER SOURCE(S): MARPAT 145:202872

AB Methods of treating metastatic cancer such as metastasized  
 tumors include administering a compound of Structure I, a tautomer of the  
 compound, a pharmaceutically acceptable salt of the compound, a  
 pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a

subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.

L8 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:428803 CAPLUS

DOCUMENT NUMBER: 141:1211

TITLE: Methods of treating cancer with a methylpiperazinyl benzimidazolyl quinolinone and related methods

INVENTOR(S): Machajewski, Timothy D.; Hannah, Alison; Harwood, Eric; Haroldsen, Peter; Heise, Carla C.; Samara, Emil; Shang, Xiao; Vora, Jayesh; Zhu, Shuguang

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043389	A2	20040527	WO 2003-US35806	20031112
WO 2004043389	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2501932	A1	20040527	CA 2003-2501932	20031112
AU 2003290699	A1	20040603	AU 2003-290699	20031112
US 2004220196	A1	20041104	US 2003-706328	20031112
EP 1565187	A2	20050824	EP 2003-783281	20031112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003016229	A	20051004	BR 2003-16229	20031112
CN 1711088	A	20051221	CN 2003-80103178	20031112
JP 2006511616	T	20060406	JP 2005-507133	20031112
NZ 539425	A	20071130	NZ 2003-539425	20031112
MX 2005PA04754	A	20050802	MX 2005-PA4754	20050503
IN 2005KN00793	A	20060303	IN 2005-KN793	20050503
NO 2005002760	A	20050720	NO 2005-2760	20050607

PRIORITY APPLN. INFO.:

US 2002-426107P	P	20021113
US 2002-426204P	P	20021113
US 2002-426282P	P	20021113
US 2003-460328P	P	20030403
US 2003-460369P	P	20030403
US 2003-460493P	P	20030403
US 2003-517915P	P	20031107
WO 2003-US35806	W	20031112

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (I) are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of I and determining a metabolic profile therefore. The growth of both the KM12L4a and MV4;11 xenografts in mice were potently inhibited by I in vivo.

L8 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:182836 CAPLUS

DOCUMENT NUMBER: 140:235711

TITLE: Preparation of benzimidazole quinolinones for inhibiting a serine/threonine kinase

INVENTOR(S): Barsanti, Paul A.; Bussiere, Dirksen; Harrison, Stephen D.; Heise, Carla C.; Jansen, Johanna M.; Jazan, Elisa; Machajewski, Timothy D.; McBride, Christopher; McCrea, William R.; Ng, Simon; Ni, Zhi-Jie; Pecchi, Sabina; Pfister, Keith; Ramurthy, Savithri; Renhowe, Paul A.; Shafer, Cynthia M.; Silver, Joel B.; Wagman, Allan; Weismann, Marion

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 570 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018419	A2	20040304	WO 2003-US25990	20030819
WO 2004018419	A3	20040603		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2496164	A1	20040304	CA 2003-2496164	20030819
AU 2003288899	A1	20040311	AU 2003-288899	20030819
EP 1539754	A2	20050615	EP 2003-781286	20030819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013743	A	20050705	BR 2003-13743	20030819
CN 1692112	A	20051102	CN 2003-824565	20030819
JP 2006503919	T	20060202	JP 2005-501762	20030819
IN 2005KN00484	A	20060106	IN 2005-KN484	20050323
PRIORITY APPLN. INFO.:			US 2002-405729P	P 20020823
			US 2002-426107P	P 20021113
			US 2002-426226P	P 20021113
			US 2002-426282P	P 20021113
			US 2002-428210P	P 20021121
			US 2003-460327P	P 20030403
			US 2003-460328P	P 20030403
			US 2003-460493P	P 20030403
			US 2003-478916P	P 20030616
			US 2003-484048P	P 20030701
			WO 2003-US25990	W 20030819
OTHER SOURCE(S):		MARPAT 140:235711		
GI				



I



II

AB The title compds. [I and II; A, B, C, and D = C, N; W, X, Y and Z = C, N and at least one of W, X, Y, and Z = N; R1-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or NR9R10 = 5-7 membered ring], useful for inhibiting various enzymes and treating various conditions, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10  $\mu$ M with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1 $\epsilon$ , Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFR $\alpha$ , and PDGFR $\beta$ . In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFR $\alpha$ , and PDGFR $\beta$  with IC50 values of less than 1  $\mu$ M.

L8 ANSWER 5 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2007:83463 USPATFULL

TITLE: Use of tyrosine kinase inhibitor to treat diabetes

INVENTOR(S): Hagerkvist, Robert Per, Hoganasgatan 7B, Uppsala, SWEDEN 75330  
Welsh, Nils Richard, Uppsala, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007072932	A1	20070329
APPLICATION INFO.:	US 2004-556984	A1	20040526 (10)
	WO 2004-EP5679		20040526
			20060622 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-12086	20030527
	GB 2004-2682	20040206
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH  
PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US  
NUMBER OF CLAIMS: 8  
EXEMPLARY CLAIM: 1-10  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 857

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit-  
tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1  
-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-  
benzamide, or a pharmaceutically acceptable salt thereof for the  
manufacture of a medicament for the treatment of diabetes, e.g. type I  
diabetes, type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2006:253838 USPATFULL  
TITLE: Combinations for the treatment of cancer  
INVENTOR(S): Chang, David, Calabasas, CA, UNITED STATES  
PATENT ASSIGNEE(S): Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006216288	A1	20060928
APPLICATION INFO.:	US 2006-386271	A1	20060321 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-664381P	20050322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1584	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is in the field of pharmaceutical agents and specifically  
relates to compounds, compositions, uses and methods for treating  
cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2006:215594 USPATFULL  
TITLE: Treatment of metastasized tumors  
INVENTOR(S): Menezes, Daniel Lopes De, Emeryville, CA, UNITED STATES  
Heise, Carla, Benicia, CA, UNITED STATES  
Xin, Xiaohua, Palo Alto, CA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006183750	A1	20060817
APPLICATION INFO.:	US 2006-342257	A1	20060127 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-647568P	20050127 (60)
	US 2005-669245P	20050406 (60)
	US 2005-722053P	20050929 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Page(s)  
LINE COUNT: 2547

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating metastatic cancer such as metastasized  
tumors include administering a compound of Structure I, a tautomer of  
the compound, a pharmaceutically acceptable salt of the compound, a  
pharmaceutically acceptable salt or the tautomer, or a mixture thereof  
to a subject. The compound, tautomer, salt of the compound, salt of the  
tautomer, or mixture thereof may be used to prepare medicaments for  
treating metastatic cancer. The variable A has the values  
defined herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:299638 USPATFULL  
TITLE: Inhibition of FGFR3 and treatment of multiple myeloma  
INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES  
Chou, Joyce, El Cerrito, CA, UNITED STATES  
Harwood, Eric, Seattle, WA, UNITED STATES  
Heise, Carla C., Benicia, CA, UNITED STATES  
Machajewski, Timothy D., Martinez, CA, UNITED STATES  
Ryckman, David, Bellevue, WA, UNITED STATES  
Shang, Xiao, Bellevue, WA, UNITED STATES  
Wiesmann, Marion, Brisbane, CA, UNITED STATES  
Zhu, Shuguang, Shoreline, WA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005261307	A1	20051124
APPLICATION INFO.:	US 2004-983174	A1	20041105 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)
	US 2003-526426P	20031202 (60)
	US 2003-526425P	20031202 (60)
	US 2004-546017P	20040219 (60)
	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 28  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 34 Drawing Page(s)  
LINE COUNT: 17221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:293608 USPATFULL  
TITLE: Combination therapy with CHK1 inhibitors  
INVENTOR(S): Gesner, Thomas G., Kensington, CA, UNITED STATES  
Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES  
Harrison, Stephen D., Albany, CA, UNITED STATES  
Ni, Zhi-Jie, Fremont, CA, UNITED STATES  
Brammeier, Nathan M., Walnut Creek, CA, UNITED STATES  
Zhou, Yasheen, Moraga, CA, UNITED STATES  
Le, Vincent P., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005256157	A1	20051117
APPLICATION INFO.:	US 2005-41191	A1	20050121 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-538984P	20040123 (60)
	US 2002-405729P	20020823 (60)
	US 2002-426282P	20021113 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 32  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 28 Drawing Page(s)  
LINE COUNT: 16679

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:275261 USPATFULL  
TITLE: Modulation of inflammatory and metastatic processes  
INVENTOR(S): Heise, Carla, Benicia, CA, UNITED STATES  
Lee, Sang H., Waltham, MA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239825	A1	20051027
APPLICATION INFO.:	US 2005-61386	A1	20050218 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-546395P	20040220 (60)
	US 2004-547103P	20040223 (60)
	US 2004-554771P	20040319 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 39  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 9 Drawing Page(s)  
LINE COUNT: 5172

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of using compounds having Structure I or the salts or tautomers  
of the compounds in the treatment of disorders relating to cell adhesion  
and metastatic processes are presented herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:241451 USPATFULL  
TITLE: Quinolinone derivatives  
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES  
Shafer, Cynthia M., Moraga, CA, UNITED STATES  
Machajewski, Timothy D., Martinez, CA, UNITED STATES  
Pecchi, Sabina, Oakland, CA, UNITED STATES  
McBride, Christopher, Oakland, CA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209456	A1	20050922
APPLICATION INFO.:	US 2005-92137	A1	20050329 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-886950, filed on 8 Jul 2004, PENDING Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, GRANTED, Pat. No. US 6774237 Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5434	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for synthesizing a 4-amino substituted quinolinone includes  
reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with  
a substituted or unsubstituted 2-aminobenzonitrile in the presence of a



base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:241242 USPATFULL

TITLE: Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties

INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES  
Chou, Joyce, El Cerrito, CA, UNITED STATES  
Harwood, Eric, Seattle, WA, UNITED STATES  
Machajewski, Timothy, Martinez, CA, UNITED STATES  
Ryckman, David, Bellevue, WA, UNITED STATES  
Shang, Xiao, Bellevue, WA, UNITED STATES  
Zhu, Shuguang, Shoreline, WA, UNITED STATES  
Okhamafe, Augustus O., Concord, CA, UNITED STATES  
Tesconi, Marc S., Monroe, NY, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209247	A1	20050922
APPLICATION INFO.:	US 2004-982543	A1	20041105 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517915P	20031107 (60)
	US 2003-526425P	20031202 (60)
	US 2003-526426P	20031202 (60)
	US 2004-546017P	20040219 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US  
NUMBER OF CLAIMS: 45  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 7116

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A lactate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R.sup.1-R.sup.9 and R.sup.12-R.sup.14 are as defined herein ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:234162 USPATFULL

TITLE: Benzimidazole quinolinones and uses thereof

INVENTOR(S): Barsanti, Paul A., Pleasant Hill, CA, UNITED STATES  
Bussiere, Dirksen, San Leandro, CA, UNITED STATES  
Harrison, Stephen D., Albany, CA, UNITED STATES  
Heise, Carla C., Benicia, CA, UNITED STATES  
Jansen, Johanna M., San Francisco, CA, UNITED STATES  
Jazan, Elisa, Berkeley, CA, UNITED STATES  
Machajewski, Timothy D., Martinez, CA, UNITED STATES  
McBride, Christopher, Oakland, CA, UNITED STATES  
McCrea, William R. JR., Berkeley, CA, UNITED STATES  
Ng, Simon, Walnut Creek, CA, UNITED STATES  
Ni, Zhi-Jie, Fremont, CA, UNITED STATES  
Pecchi, Sabina, Oakland, CA, UNITED STATES  
Pfister, Keith B., San Ramon, CA, UNITED STATES  
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES  
Renhowe, Paul A., Danville, CA, UNITED STATES

Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
Silver, Joel B., Santa Cruz, CA, UNITED STATES  
Wagman, Allan S., Belmont, CA, UNITED STATES  
Wiesmann, Marion, Brisbane, CA, UNITED STATES  
Wayman, Kelly, San Rafael, CA, UNITED STATES  
Chiron Corporation (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005203101	A1	20050915
APPLICATION INFO.:	US 2004-839793	A1	20040505 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-644055, filed on 19 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

NUMBER OF CLAIMS: 9  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Page(s)  
LINE COUNT: 14866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 23 USPATFULL on STN  
ACCESSION NUMBER: 2005:159189 USPATFULL  
TITLE: Methods for synthesizing quinolinone compounds  
INVENTOR(S): Cai, Shaopei, Seattle, WA, UNITED STATES  
Chou, Joyce, El Cerrito, CA, UNITED STATES  
Harwood, Eric, Seattle, WA, UNITED STATES  
Machajewski, Timothy, Martinez, CA, UNITED STATES  
Ryckman, David, Bellevue, WA, UNITED STATES  
Shang, Xiao, Bellevue, WA, UNITED STATES  
Zhu, Shuguang, Shoreline, WA, UNITED STATES  
Okhamafe, Augustus O., Concord, CA, UNITED STATES  
Tesconi, Marc S., Monroe, NY, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005137399	A1	20050623
APPLICATION INFO.:	US 2004-982757	A1	20041105 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2003-517915P 20031107 (60)  
US 2003-526425P 20031202 (60)  
US 2003-526426P 20031202 (60)  
US 2004-546017P 20040219 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097, US

NUMBER OF CLAIMS: 71  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2006

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of synthesizing a substituted or unsubstituted  
4-amino-3-benzimidazolyl quinolinone compound includes reacting a first  
compound having the formula I with a second compound having the formula  
II in a suitable solvent in the presence of a sodium or potassium salt  
of a base. The first compound and the second compound have the following  
structures where the variables have the values described herein:  
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:63630 USPATFULL  
TITLE: Quinolinone derivatives  
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES  
Pecchi, Sabina, Oakland, CA, UNITED STATES  
Machajewski, Timothy D., Martinez, CA, UNITED STATES  
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
Taylor, Clarke, Albany, CA, UNITED STATES  
McCrea, William R., Berkeley, CA, UNITED STATES  
McBride, Christopher, Oakland, CA, UNITED STATES  
Jazan, Elisa, Richmond, CA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005054672	A1	20050310
APPLICATION INFO.:	US 2004-886950	A1	20040708 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, GRANTED, Pat. No. US 6774237 Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Young J. Suh, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5757	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Organic compounds having the formula I are provided where the variables  
have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or  
pharmaceutically acceptable salts thereof and a pharmaceutically  
acceptable carrier and may be prepared by mixing the organic compounds  
or pharmaceutically acceptable salts of the organic compounds with a  
carrier and water. A method of treating a patient includes administering  
a pharmaceutical formulation according to the invention to a patient in  
need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2005:44347 USPATFULL

TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for

the treatment and prevention of diseases and conditions

INVENTOR(S): Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF

Dumas, Jacques, Bethany, CT, UNITED STATES

Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF

Wilhelm, Scott, Orange, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005038080	A1	20050217
APPLICATION INFO.:	US 2004-895985	A1	20040722 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-489102P	20030723 (60)
	US 2004-540326P	20040202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2492	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of Formula (I): ##STR1##

salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:280895 USPATFULL

TITLE: Methods of treating cancer and related methods

INVENTOR(S): Hannah, Alison, Sebastopol, CA, UNITED STATES

Harwood, Eric, Seattle, WA, UNITED STATES

Haroldsen, Peter, Pacifica, CA, UNITED STATES

Heise, Carla, Benecia, CA, UNITED STATES

Machajewski, Timothy, Martinez, CA, UNITED STATES

Samara, Emil, Danville, CA, UNITED STATES

Shang, Xiao, Bellevue, WA, UNITED STATES

Vora, Jayesh, Martinez, CA, UNITED STATES

Zhu, Shuguang, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220196	A1	20041104
APPLICATION INFO.:	US 2003-706328	A1	20031112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-460369P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460328P	20030403 (60)
	US 2002-426204P	20021113 (60)
	US 2002-426282P	20021113 (60)

US 2002-426107P 20021113 (60)  
US 2003-517915P 20031107 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097  
NUMBER OF CLAIMS: 58  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 2045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating cancer using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one are provided. In particular, the methods are effective for the treatment of solid tumors or leukemias, including prostate, colorectal, breast, multiple myeloma, pancreatic, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, or myelo-proliferative disease. Further provided are methods of measuring the amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one and determining a metabolic profile therefore.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:127561 USPATFULL  
TITLE: Quinolinone derivatives  
INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES  
Pecchi, Sabina, Oakland, CA, UNITED STATES  
Machajewski, Timothy D., Martinez, CA, UNITED STATES  
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
Taylor, Clarke, Ann Arbor, MI, UNITED STATES  
McCrea, William R., JR., Berkeley, CA, UNITED STATES  
McBride, Christopher, Oakland, CA, UNITED STATES  
Jazan, Elisa, Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097545	A1	20040520
	US 6800760	B2	20041005
APPLICATION INFO.:	US 2003-613411	A1	20030703 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6582	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:121119 USPATFULL  
TITLE: Benzimidazole quinolinones and uses thereof  
INVENTOR(S): Barsanti, Paul A., Walnut Creek, CA, UNITED STATES  
Bussiere, Dirksen, San Leandro, CA, UNITED STATES  
Harrison, Stephen D., Albany, CA, UNITED STATES  
Heise, Carla C., Benicia, CA, UNITED STATES  
Jansen, Johanna M., San Francisco, CA, UNITED STATES  
Jazan, Elisa, Richmond, CA, UNITED STATES  
Michajewski, Timothy D., Martinez, CA, UNITED STATES  
McBride, Christopher, Oakland, CA, UNITED STATES  
McCrea, William R., JR., Berkeley, CA, UNITED STATES  
Ng, Simon, Walnut Creek, CA, UNITED STATES  
Ni, Zhi-Jie, Fremont, CA, UNITED STATES  
Pecchi, Sabina, Oakland, CA, UNITED STATES  
Pfister, Keith B., San Ramon, CA, UNITED STATES  
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES  
Renhowe, Paul A., Danville, CA, UNITED STATES  
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
Silver, Joel B., Concord, NH, UNITED STATES  
Wagman, Allan S., Belmont, CA, UNITED STATES  
Wiesmann, Marion, Brisbane, CA, UNITED STATES  
PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004092535	A1	20040513
APPLICATION INFO.:	US 2003-644055	A1	20030819 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-405729P	20020823 (60)
	US 2002-426107P	20021113 (60)
	US 2002-426226P	20021113 (60)
	US 2002-426282P	20021113 (60)
	US 2002-428210P	20021121 (60)
	US 2003-460328P	20030403 (60)
	US 2003-460493P	20030403 (60)
	US 2003-460327P	20030403 (60)
	US 2003-478916P	20030616 (60)
	US 2003-484048P	20030701 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097  
NUMBER OF CLAIMS: 68  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Page(s)  
LINE COUNT: 18050

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2004:7861 USPATFULL

TITLE: Quinolinone derivatives  
 INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES  
 Pecchi, Sabina, Oakland, CA, UNITED STATES  
 Machajewski, Timothy D., Martinez, CA, UNITED STATES  
 Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
 Taylor, Clarke, Ann Arbor, MI, UNITED STATES  
 McCrea, William R., JR., Berkeley, CA, UNITED STATES  
 McBride, Christopher, Oakland, CA, UNITED STATES  
 Jazan, Eliza, Richmond, CA, UNITED STATES  
 PATENT ASSIGNEE(S): CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006101	A1	20040108
	US 6762194	B2	20040713
APPLICATION INFO.:	US 2003-387355	A1	20030312 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-284017, filed on 30 Oct 2002, PENDING Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, GRANTED, Pat. No. US 6605617		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven W. Collier, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2003:226411 USPATFULL  
 TITLE: Quinolinone derivatives  
 INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES  
 Pecchi, Sabina, Oakland, CA, UNITED STATES  
 Machajewski, Timothy D., Martinez, CA, UNITED STATES  
 Shafer, Cynthia M., El Sobrante, CA, UNITED STATES  
 Taylor, Clarke, Ann Arbor, MI, UNITED STATES  
 McCrea Jr, William R., Berkeley, CA, UNITED STATES  
 McBride, Christopher, Oakland, CA, UNITED STATES  
 Jazan, Elisa, Richmond, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158224	A1	20030821
	US 6774237	B2	20040810
APPLICATION INFO.:	US 2002-284017	A1	20021030 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-951265, filed on 11 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven W. Collier, Chiron Corporation, P.O. Box 8097, Emeryville, CA, 94662	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5881	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##	

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2003:38371	USPATFULL
TITLE:	Quinolinone derivatives	
INVENTOR(S):	Renhowe, Paul A., Danville, CA, UNITED STATES	
	Pecchi, Sabina, Oakland, CA, UNITED STATES	
	Machajewski, Timothy D, Martinez, CA, UNITED STATES	
	Shafer, Cynthia M., El Sobrante, CA, UNITED STATES	
	Taylor, Clarke, Ann Arbor, MI, UNITED STATES	
	McCrea, William R., JR., Berkeley, CA, UNITED STATES	
	McBride, Christopher, Oakland, CA, UNITED STATES	
	Jazan, Elisa, Richmond, CA, UNITED STATES	
PATENT ASSIGNEE(S):	Chiron Coporation (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003028018	A1	20030206
APPLICATION INFO.:	US 2002-116117	A1	20020405 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-951265, filed on 11 Sep 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property Law Dept., PO Box 8097, Emeryville, CA, 94662	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6573	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##	

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in



need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:199281 USPATFULL

TITLE: Quinolinone derivatives

INVENTOR(S): Renhowe, Paul A., Danville, CA, UNITED STATES

Pecchi, Sabina, Oakland, CA, UNITED STATES

Machajewski, Timothy D., Martinez, CA, UNITED STATES

Shafer, Cynthia M., El Sobrante, CA, UNITED STATES

Taylor, Clarke, Ann Arbor, MI, UNITED STATES

McCrea, William R., JR., Berkeley, CA, UNITED STATES

McBride, Christopher, Oakland, CA, UNITED STATES

Jazan, Elisa, Richmond, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002107392	A1	20020808
	US 6605617	B2	20030812
APPLICATION INFO.:	US 2001-951265	A1	20010911 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232159P	20000911 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David Lentini, CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA, 94608-2916	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6588	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Organic compounds having the formulas I and II are provided where the variables have the values described herein. ##STR1##

Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:00:50 ON 01 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 01 FEB 2008

L1 STRUCTURE UPLOADED

L2 0 S L1 EXA

L3 2 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:02:32 ON 01 FEB 2008

L4 0 S L2

L5 41 S L3

L6 2 S L5 AND (CMAX OR AUC)

L7 27 S L5 AND (CANCER OR TUMOR)

L8 23 S L7 AND "TYROSINE KINASE"

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	92.93	159.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 15:09:27 ON 01 FEB 2008